Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Morten K. Jensen et al.|The Lancet|2020Cited by 1.2k
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|Journal of the American College of Cardiology|2023Cited by 192
Automated Echocardiographic Quantification of Left Ventricular Ejection Fraction Without Volume Measurements Using a Machine Learning Algorithm Mimicking a Human ExpertFederico M. Asch, Roberto M. Lang, Nicolas Poilvert et al.|Circulation Cardiovascular Imaging|2019Cited by 188
Mavacamten in Symptomatic Nonobstructive Hypertrophic CardiomyopathyMilind Y. Desai, Steven E. Nissen, Anjali Owens et al.|New England Journal of Medicine|2025Cited by 51